We are delighted to hear that Dr Kam Pooni, CEO at Deepbridge investee company Glyconics, has been listed for Cofinitive's Top 21 to Watch shortlist. 

 Out of the hundreds entries received, 207 qualified candidates that made it onto a longlist, which has now been whittled down to a shortlist of 62, featuring a dynamic mix of ‘People’, ‘Companies’ and ‘Things’.

You can see the full list here.

(By following this link, you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).

About Glyconics 

Glyconics Ltd is aiming to develop an innovative approach to the diagnosis and monitoring of chronic and acute diseases including respiratory disease.

The Company is seeking to develop a new hand-held miniaturised device to aim to effectively diagnose and predict the exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in patients at the point of care.  The Company’s aim is to optimise the hand-held, miniaturised device for easy detection of disease monitoring by healthcare workers at the point-of-care.